By Lisa Kerner
Charlotte, N.C., Sept. 7 - Metastatix, Inc. completed a $3.6 million series A financing round.
Proceeds will be used to develop initial clinical candidates and advance the cancer program to filing of an Investigational New Drug application.
H.I.G. Ventures led the round, joined by The Aurora Funds, CM Capital, SR One, MedImmune Ventures, Inc., Georgia Venture Partners, Centrosome Ventures and the State of Georgia.
Bruce Robertson, managing director of H.I.G. Ventures, will become chairman of the board for Metastatix.
Doug Gooding of The Aurora Funds, Ad Rawcliffe of SR One and Wayne T. Hockmeyer of MedImmune Ventures will join the Metastatix board of directors.
Metastatix is an Atlanta-based biopharmaceutical company.
| Issuer: | Metastatix, Inc.
|
| Issue: | Series A financing
|
| Amount: | $3.6 million
|
| Investors: | H.I.G. Ventures (lead), The Aurora Funds, CM Capital, SR One, MedImmune Ventures, Inc., Georgia Venture Partners, Centrosome Ventures, the State of Georgia.
|
| Announcement date: | Sept. 7
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
